Sarepta Therapeutics (SRPT) Eteplirsen Dosing Said Delayed Until Oct./Nov.
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
(Updated - September 19, 2014 3:23 PM EDT)
Sarepta Therapeutics (NASDAQ: SRPT) eteplirsen trial start delay until Oct./Nov., according to the Boston Business Journal.
UPDATE - Sarepta CEO Chris Garabedian previously said the eteplirsen trial would begin in September. The firm has already begun enrolling50 to 80 patients.
Eteplirsen is a proposed treatment for Duchenne muscular dystrophy (DMD).
During an interview today, Garabedian said Initiating five new treatment studies requires a significant effort to prepare, and we’re doing all of this as fast as we can .. There's a lot that we're trying to accomplish in a short period of time.
News comes as Prosensa Holding N.V. (Nasdaq: RNA) announced earlier this week that a comprehensive program of re-dosing has commenced, with the first patients now re-dosed in the United States. All dosing in the drisapersen clinical program had been placed on hold by GSK on September 20, 2013, upon announcement of the DEMAND III study results.
Sarepta is down 4 percent Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alibaba's (BABA) Ant Group Appoints Han Xinyi as President - Reuters
- CC Capital Is Among Parties In Talks To Acquire Soho House & Co (SHCO) -sources - Reuters
- Dick's Sporting Goods (DKS) stock up on Q4 beat, dividend hike
Create E-mail Alert Related Categories
Insiders' Blog, Management Comments, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!